Program
darleukin
Also written as “L19IL2”, “L19IL2 + L19TNF” and “L19IL2 +L19TNF”.
Its studies are mostly in Melanoma · Carcinoma, Basal Cell · Colorectal Neoplasms · Pancreatic Neoplasms · Carcinoma, Renal Cell, led by Philogen.
Furthest: phase 3, since Oct 11, 20169 company-led studies, 5 open or runningNext primary completion: Jul 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Philogen | 95 open or running | phase 3since Oct 11, 2016 | Jan 22, 2010 | Jul 2028phase 2 · NCT06284590 |
Also a collaborator on its studies: Merck and eudax-s-r-l.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 22, 2010First studies: 2 phase 2 studiesFirst studyNCT01055522, NCT01058538
- Sep 8, 2010Phase 1 study in Pancreatic NeoplasmsNCT01198522 · 28 enrolled · Germany, Italy
- Feb 24, 2014Phase 2 study in MelanomaNCT02076633 · 21 enrolled · Italy
- Oct 11, 2016Phase 3 study in MelanomaNCT02938299 · 214 enrolled · France, Germany, Italy and more
- Apr 17, 2020Phase 2 study in Carcinoma, Basal CellNCT04362722 · 40 planned · Germany, Poland, Switzerland
- Jan 26, 2024Phase 2 study in MelanomaNCT06284590 · 162 planned · United States, Germany, Italy
- Nov 7, 2025Phase 2 study in Carcinoma, Basal CellNCT07227350 · 180 planned · United States, Germany, Greece and more
- Apr 15, 2026Phase 1 study in Colorectal NeoplasmsNCT07566897 · 96 planned · Italy
Ahead
- Jul 2028Primary completion: phase 2 study in MelanomaNCT06284590
- Dec 2029Primary completion: phase 1 study in Colorectal NeoplasmsNCT07566897
- Feb 2031Primary completion: phase 2 study in Carcinoma, Basal CellNCT07227350
TargetBeta
IL2 →read by rule
“An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) ”NCIt, by rule
Other programs on IL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daromunrule | Philogen | phase 3 | 6 |
| Daxokafusp Alfa | Sanofi | phase 2 | 2 |
| SAR444336 | Sanofi | phase 2 | 2 |
| Anti-PD-1/IL-2 Fusion Protein TEV-56278 | Teva Pharmaceutical Industries | phase 1 | 2 |
| IL-2 Mutein/Fc Fusion Protein HM16390rule | Hanmi Pharmaceutical | phase 1 | 1 |
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | outpace-bio-inc | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07566897Colorectal Neoplasms · Italy | 1 | Not yet recruiting | Dec 2029 | 96 |
| NCT07227350Carcinoma, Basal Cell · United States, Germany, Greece and more | 2 | Recruiting | Feb 2031 | 180 |
| NCT06284590Melanoma · United States, Germany, Italy | 2 | Recruiting | Jul 2028 | 162 |
| NCT04362722Carcinoma, Basal Cell · Germany, Poland, Switzerland | 2 | Recruiting | Sep 2024 | 40 |
| NCT02938299Melanoma · France, Germany, Italy and more | 3 | Active, not recruiting | Oct 2024 | 214 |
| NCT02076633Melanoma · Italy | 2 | Completed | May 2015 | 21 |
| NCT01198522Pancreatic Neoplasms · Germany, Italy | 1 | Terminated | Nov 2014 | 28 |
| NCT01058538Carcinoma, Renal Cell · Germany, Italy | 2 | Completed | Apr 2008 | 33 |
| NCT01055522Melanoma · Austria, Germany, Italy and more | 2 | Terminated | Feb 2013 | 102 |
How it is read
Names in the registry
- “L19IL2”, 4 entries
- “L19IL2 + L19TNF”, 1 entry
- “L19IL2 +L19TNF”, 1 entry
- “L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine”, 1 entry
- “L19IL2+L19TNF”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 4 studies
- Carcinoma, Basal Cell, 2 studies
- Colorectal Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.